Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | CCR1 | P32246 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5711785 | 0.87 | ALDH1A1 (0.46) | NPC1MEN1KMT2ACCR1ALDH1A1 | |
| SCHEMBL9977973 | 0.87 | KMT2A (0.38) | LMNANPC1MEN1KMT2ACCR1 | |
| SCHEMBL9978129 | 0.87 | KMT2A (0.38) | LMNANPC1MEN1KMT2ACCR1 | |
| SCHEMBL9978080 | 0.87 | KMT2A (0.38) | LMNANPC1MEN1KMT2ACCR1 | |
| SCHEMBL14243021 | 0.86 | LMNA (0.45) | LMNANPC1TDP1MEN1KMT2A | |
| SCHEMBL17293251 | 0.85 | NPC1 (0.31) | LMNANPC1KMT2APOLB | |
| SCHEMBL1563090 | 0.83 | POLB (0.45) | LMNAMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL17293485 | 0.83 | ALDH1A1 (0.40) | LMNATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL9977981 | 0.83 | POLB (0.34) | LMNANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL17293646 | 0.83 | NPC1 (0.38) | LMNANPC1KMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651932-B1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-11-25 | — | — | EP | disclosed |
| US-8648070-B2 | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648070-B2 | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2012080457-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316159-A1 | BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | CXCR2, CCR2, SULT2A1 | LMNA 4805/4885NPC1 2701/4885TDP1 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.